Prospective evaluation of aluminum loading from formula in infants with uremia.
Assessment of potential aluminum loading from regular ingestion of a commercial infant formula (Similac PM 60/40), as the only milk substitute, was made in 14 infants aged 9.6 +/- 4.4 months who were also undergoing continuous cycling peritoneal dialysis. Tissue aluminum accumulation was assessed by serial measurements of plasma aluminum levels, from the increment in plasma aluminum after a standardized deferoxamine infusion, and from quantitative histomorphometry of bone and measurements of total bone aluminum content. Initial mean plasma aluminum levels were 0.61 +/- 0.32 mumol/L, (normal 0.30 +/- 0.04 mumol/L), and values were less than 0.92 mumol/L during the follow-up of 20 +/- 8 months. Plasma aluminum levels increased from 0.59 +/- 0.18 to 0.88 +/- 0.22 mumol/L after a single dose of deferoxamine. The histochemical stain for bone aluminum was negative for all patients, and the bone aluminum content was 0.27 +/- 0.22 mmol/kg dry weight (normal 0.08 +/- 0.04 mmol/kg dry weight). Thus the infant formula Similac PM 60/40 can be safely used in infants with chronic renal failure.
Salusky
I B
IB
Department of Pediatrics, University of California, School of Medicine, Los Angeles.
Coburn
J W
JW
Nelson
P
P
Goodman
W G
WG
D000535:Aluminum / Q000032:analysis* / Q000097:blood; D001842:Bone and Bones / Q000032:analysis; D003676:Deferoxamine; D015314:Dialysis Solutions / Q000032:analysis; D005500:Follow-Up Studies; D006651:Histocytochemistry; D006801:Humans; D007223:Infant; D007225:Infant Food / Q000032:analysis; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000628:therapy; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011446:Prospective Studies; D013054:Spectrophotometry, Atomic; D014018:Tissue Distribution; D014511:Uremia / Q000378:metabolism*
D015314:Dialysis Solutions; D000535:Aluminum; D003676:Deferoxamine